Allogene Therapeutics ALLO 深 沪
已收盘 12-19 16:00:00 美东时间
1.405
-0.015
-1.06%
华盛通- 最 高1.565
- 今 开1.42
- 成交量 496.29万股
- 最 低 1.30
- 昨 收 1.42
- 总市值 2.02亿
- 52周最高 3.7799
- 市盈率 静 --
- 换手率 3.45%
- 52周最低 0.8621
- 委 比 11.08%
- 总股本 1.44亿
- 历史最高 55.00
- 量 比 2.29
- 振 幅 18.66%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.
12-17 02:09
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Allogene Therapeutics reported that ALLO-316, an allogeneic CAR T therapy targeting CD70, showed a 31% response rate in CD70-positive advanced RCC patients, with four out of five responders maintaining their response and one achieving remission over 12 months. The Phase 1 trial demonstrated efficient CAR T cell expansion and tumor infiltration, alongside manageable safety profiles, underscoring its potential in solid tumor treatment.
06-01 14:45
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics' obe-cel CAR T-cell therapy received a positive CHMP opinion, based on the FELIX trial showing high response rates and low toxicity for adult r/r B-ALL patients. The EC is expected to decide on conditional marketing authorization within two months, following FDA and MHRA approvals.
05-23 12:30
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
<p>Allogene Therapeutics将参与五月底至六月底的四场投资者会议，详情请访问其官网www.allogene.com获取直播链接。</p>
05-23 12:30
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
<p>Allogene Therapeutics announced the upcoming presentation of two abstracts at the 2025 ASCO Annual Meeting: updated data on ALLO-316, an investigational CAR T product targeting CD70 in renal cell carcinoma, and the design of the pivotal Phase 2 ALPHA3 trial evaluating cema-cel for large B-cell lymphoma. The presentations will highlight advancements in allogeneic CAR T therapy, addressing unmet needs in treating solid tumors and improving lymphoma outcomes.</p>
05-22 21:17
Poseida Therapeutics To Present New Clinical Data From Phase 1 Study Of Allogeneic CAR-T P-BCMA-ALLO1 In Patients With Relapsed/Refractory Multiple Myeloma At 21st International Myeloma Society Annual Meeting; Initiation Of P-BCMA-ALLO1 Phase 1b Clinical Trial In Patients With Multiple Myeloma, Generated $20M Payment From Roche
Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platformCompany to host conference call on Saturday, September 28, 2024, at
2024-09-05 21:14
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $9 price target.
2024-08-15 19:04
